title: Anti-obesity and anti-diabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance.
abstract: OBJECTIVE
  Obesity in rodents and humans is mostly associated with elevated plasma leptin concentrations, suggesting a new pathological concept of 'leptin resistance'. We have demonstrated that brain-derived neurotrophic factor (BDNF) can improve obesity and diabetes of C57BL/KsJ db/db (db/db) mice. In this study, we investigated whether or not BDNF is effective in two different models of leptin resistance, an acquired model and a genetic model.
  
  
  METHODS
  C57BL/6J mice rendered obese by consumption of a high-fat diet (diet-induced obesity (DIO) mice) were used as an acquired model and lethal yellow agouti mice (KKA(y) mice) as a genetic model of leptin resistance. Food intake and glucose metabolism were studied after acute or repetitive administration of BDNF.
  
  
  RESULTS
  Intraperitoneal administration of BDNF (10 mg/kg, twice/day) significantly reduced cumulative food intake of DIO and KKA(y) mice, whereas they were unresponsive to leptin administration. Repetitive subcutaneous administration of BDNF (10 mg/kg daily for 6 days) reduced food intake and improved impaired glucose tolerance in DIO mice. Pair feeding of vehicle-treated DIO mice with the same amount of chow consumed by the BDNF-treated group did not improve the impaired glucose homeostasis, indicating that the antidiabetic effect is not due to decreased food intake. We also observed that BDNF is effective in improving obesity and diabetes of KKA(y) mice.
  
  
  CONCLUSIONS
  This study demonstrated antiobesity and antidiabetic effects of BDNF in two different models of leptin resistance, thereby suggesting the therapeutic potential of BDNF in the treatment of leptin-resistant obesity and diabetes.
authors.affiliation: Discovery Research Laboatories I, Sumitomo Pharmaceuticals Research Division, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: K
authors.initials: K
authors.lastname: Ebihara
authors.forename: M
authors.initials: M
authors.lastname: Yamanaka
authors.forename: A
authors.initials: A
authors.lastname: Tsuchida
authors.forename: M
authors.initials: M
authors.lastname: Taiji
authors.forename: H
authors.initials: H
authors.lastname: Noguchi
authors.forename: K
authors.initials: K
authors.lastname: Nakao
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D019208:Brain-Derived Neurotrophic Factor / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D004435:Eating / Q000187:drug effects; D005951:Glucose Tolerance Test; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000097:blood / Q000188:drug therapy*
chemical_list: D001786:Blood Glucose; D019208:Brain-Derived Neurotrophic Factor; D007328:Insulin; D020738:Leptin